Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 6, 2017. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMR) and persons closely associated with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively reports specific share transaction details:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction 1: Sale of 98,581.776 shares at a price of £16.8006 per share.
- Transaction 2: Sale of 131,418 shares at a price of £16.835 per share.
- Total Volume Reported: 229,999.776 shares sold.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It solely discloses the reduction in shareholdings of specific individuals on the reporting date.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is a regulatory disclosure of insider trading activity.
Investor Verification Points
- Verify the identity of the sellers: Mr. S A Hussain (President, Global Pharmaceuticals) and Mrs. S G Hussain (Person Closely Associated).
- Confirm the total number of shares sold by these individuals on March 6, 2017, against their remaining holdings.
- Note that the transaction prices (£16.8006 and £16.835) reflect the market price on the London Stock Exchange at the time of execution.